Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 3/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N6-Cyclopentyladenosine SCHEMBL12226873 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL7202975 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL8271466 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL381792 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL472621 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL12200134 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL20226050 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL120481 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL18908968 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| SCHEMBL12119008 | 0.99 | TSHR (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| WO-2013049585-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | HENGRUI (USA), LTD. (US) | 2013-04-04 | — | — | WO | claimed |
| EP-2555775-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | Inotek Pharmaceuticals Corporation (US) | 2013-02-13 | — | — | EP | claimed |
| WO-2011116290-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-09-22 | — | — | WO | claimed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-2412716-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7696181-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | IBRAHIM PRABHA | 2009-12-31 | — | — | US | disclosed |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | IBRAHIM PRABHA | 2006-12-21 | — | — | US | disclosed |
| US-7144871-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1476455-A1 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003070739-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885TSHR 88/4885 |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885TSHR 88/4885 |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885TSHR 443/4885 |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885TSHR 89/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | ADORA3 13/4885ADORA2A 3/4885TSHR 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.